IN8bio, Inc.
INABAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 13, 2025 | Mizuho Securities | $4.00(+90%) | $2.11 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 12, 2025 |
| Jones Trading | upgrade | Hold →Buy | Feb 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2024 |
| Jones Trading | downgrade | Buy →Hold | Aug 12, 2024 |
| Jones Trading | maintain | Buy | Jun 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| EF Hutton | maintain | Buy | Jun 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2023 |
| EF Hutton | maintain | Buy | Apr 17, 2023 |
| B. Riley Securities | downgrade | Buy →Neutral | Nov 11, 2022 |
| B. Riley Securities | maintain | Buy | Jan 24, 2022 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.65| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.24 | $-0.34 | — | — |
| Aug 6, 2026 | $-0.25 | $-0.34 | — | — |
| May 7, 2026 | $-0.26 | $-0.59 | — | — |
| Mar 12, 2026 | $-0.26 | $-0.18 | — | $16.0M |
| Nov 6, 2025 | $-0.85 | $-1.20 | — | $5.8M |
| Aug 7, 2025 | $-1.24 | $-1.50 | — | — |
| May 7, 2025 | $-2.10 | $-1.80 | — | — |
| Mar 13, 2025 | $-1.20 | $-0.07 | — | — |
News
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares of its common stock. The award was approved by the Compensation Committee of the C…
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 60,000 shares of its common stock. The award was approved by the Compensation Committee of the …
IN8bio (NASDAQ: INAB) outlined updates across its gamma-delta T-cell programs in autoimmune disease and oncology, including preclinical plans for its T-cell engager platform and clinical data in glioblastoma. President, CEO and Co-Founder Will Ho said the clinical-stage biotechnology company is developing therapies designed to use gamma-delta T cells, a less abundant subset of immune cells that
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026.
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C.
Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the appoin…